Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: A meta-analysis of randomised controlled trials

International Journal of Antimicrobial Agents

Volumn 36, Issue 1, 2010, Pages 58-65

  An, Mao Mao ^a   Zou, Zui ^b   Shen, Hui ^c   Gao, Ping Hui ^a   Cao, Yong Bing ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUWAI HOSPITAL   (China)

Author keywords

Lactams; Community acquired pneumonia; Meta analysis; Moxifloxacin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; ROXITHROMYCIN;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LIVER FUNCTION TEST; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953020737     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.010     Document Type: Article

References (40)

1. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001, 163:1730-1754.
2. Rello J., Catalán M., Díaz E., Bodí M., Alvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002, 28:1030-1035.
3. Appelbaum P.C. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002, 34:1613-1620.
4. Metlay J.P. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002, 15:163-167.
5. File T.M. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 34(Suppl. 1):S17-S26.
6. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl. 2):S27-S72.
7. Brueggemann A.B., Kugler K.C., Doern G.V. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997, 41:1594-1597.
8. Jones M.E., Staples A.M., Critchley I., Thornsberry C., Heinze P., Engler H.D., et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother 2000, 44:2645-2652.
9. Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999, 43:1-11.
10. MacGowan A.P., Bowker K.E., Holt H.A., Wootton M., Reeves D.S. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997, 40:503-509.
11. Nightingale C.H. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000, 20:245-256.
12. Miravittles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005, 6:283-293.
13. Bébéar C.M., Renaudin H., Boudjadja A., Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 1998, 42:703-704.
14. Roblin P.M., Hammerschlag M.R. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998, 42:951-952.
15. Ruckdeschel G., Dalhoff A. The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results. J Antimicrob Chemother 1999, 43(Suppl. B):25-29.
16. Boswell F.J., Andrews J.M., Jevons G., Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002, 50:495-502.
17. Finch R., Schürmann D., Collins O., Kubin R., McGivern J., Bobbaers H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002, 46:1746-1754.
18. Katz E., Larsen L.S., Fogarty C.M., Hamed K., Song J., Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004, 27:395-405.
19. Petitpretz P., Arvis P., Marel M., Moita J., Urueta J. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001, 119:185-195. CAP5 Moxifloxacin Study Group.
20. Portier H., Brambilla C., Garre M., Paganin F., Poubeau P., Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005, 24:367-376.
21. Torres A., Garau J., Arvis P., Carlet J., Choudhri S., Kureishi A., et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study-a randomized clinical trial. Clin Infect Dis 2008, 46:1499-1509.
22. Welte T., Petermann W., Schürmann D., Bauer T.T., Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005, 41:1697-1705.
23. Xu S., Xiong S., Xu Y., Liu J., Liu H., Zhao J., et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technol Med Sci 2006, 26:421-424.
24. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
25. Khan K.S., Daya S., Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996, 156:661-666.
26. Moher D., Jadad A.R., Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996, 12:195-208.
27. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., Song F. Methods for meta-analysis in medical research 2000, Wiley, Chichester, UK.
28. Vardakas K.Z., Siempos I.I., Grammatikos A., Athanassa Z., Korbila I.P., Falagas M.E. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008, 179:1269-1277.
29. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. Symp Ser Soc Appl Microbiol 2002, 31(Suppl.):55S-64S.
30. Krasemann C., Meyer J., Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001, 32(Suppl. 1):S51-S63.
31. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001, 32(Suppl. 1):S16-S22.
32. Drlica K., Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007, 44:681-688.
33. Blondeau J.M., Zhao X., Hansen G., Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001, 45:433-438.
34. Hesje C.K., Tillotson G.S., Blondeau J.M. MICs, MPDs and PK/PDs: a match (sometimes) made in hosts. Expert Rev Respir Med 2007, 1:7-16.
35. Simoens S. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Curr Med Res Opin 2009, 25:2447-2457.
36. Davis S.L., Delgado G., McKinnon P.S. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005, 41(Suppl. 2):S136-S143.
37. Higgins J., Thompson S., Deeks J., Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002, 7:51-61.
38. Sterne J.A.C., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001, 54:1046-1055.
39. Lau J., Ioannidis J.P.A., Schmid C.H. Summing up the evidence: one answer is not always enough. Lancet 1997, 351:123-127.
40. Thompson S.G. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994, 309:1351-1355.